Cell Biology
GLP-3RT
Investigational multi-receptor peptide for laboratory research
investigational, chemically modified peptide studied in experimental glucagon, GIP, and GLP-1 receptor-signaling models. It has not been approved by the U.S. FDA for general clinical use. Offered strictly for laboratory research use only. Not for human or veterinary use.
Frequently researched together
Other laboratory research compounds available in our catalog.
Compound information
Technical specifications
What is GLP-3RT?
GLP-3 RT, catalogued as GLP-3RT, is a synthetic 39-residue peptide whose sequence corresponds to a chemically modified backbone drawn from the glucagon and incretin peptide family. The catalogue classes it as a GIP, GLP-1 and glucagon receptor agonist peptide analogue: a single synthetic chain designed to carry affinity for three related class B G-protein-coupled receptors, those for glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon. The catalogue records the material as investigational and states that it has not been approved by the U.S. Food and Drug Administration for general clinical use.
The identifier recorded in the catalogue entry is the molecular formula, C221H342N46O68. A CAS registry number is not catalogued here and a molecular weight is not catalogued here, so neither value is stated. The full residue sequence and the positions of the modifications are likewise not recorded, and no sequence is asserted on this page. Modification strategies general to the class include substitution of non-natural residues at cleavage-sensitive positions and side-chain acylation with a fatty-acid moiety. The material is listed under cell biology, is supplied lyophilized in a 10 mg vial, and carries no alternative catalogue synonyms.
Purity and identity are established by third-party HPLC and mass spectrometry, with a certificate of analysis for each lot. GLP-3 RT is supplied strictly for laboratory research and is not for human or veterinary use, nor for consumption, administration, diagnostic use or therapeutic use.
- Molecular formula
- C221H342N46O68
Stability information
Recommended handling and storage conditions for retaining compound identity and integrity in the laboratory.
Store lyophilized at −20°C, protected from light. Reconstitute and refrigerate (2–8°C) for short-term research use.
Regulatory information
Development origin and regulatory status, compiled for reference.
Research compound · Not FDA-approved
Frequently asked
Questions about GLP-3RT
What purity is GLP-3RT supplied at, and is a Certificate of Analysis available?
Yes. Each lot of GLP-3RT is tested by a third-party laboratory using HPLC for purity, and the certificate of analysis for the current lot is linked on this page and in the certificate library.
How is the identity of GLP-3RT verified?
Identity is confirmed by mass spectrometry against the expected molecular weight, alongside HPLC retention behaviour. Both results are recorded on the lot certificate.
How should GLP-3RT be stored on receipt?
Lyophilized material is stored at -20 C protected from light. Once reconstituted it is kept at 2 to 8 C for short-term laboratory use, and repeated freeze-thaw cycles are avoided.
Where is GLP-3RT shipped from?
Orders ship from the United States in discreet, tracked packaging. Shipping is available to US addresses only.
Is GLP-3RT supplied for research use only?
Yes. GLP-3RT is sold strictly as a laboratory research material. It is not for human or veterinary use, not for diagnostic procedures, and has not been evaluated by the U.S. Food and Drug Administration. See the research use disclaimer for the full terms.
Answers describe how this material is tested, stored and shipped. They are not guidance on any use, and this compound is not for human or veterinary use.
Sources & references
Published literature in which this compound has been the subject of laboratory or preclinical study. Listed for bibliographic reference only.
Research and educational purposes only. These references are provided for bibliographic context. They are not evidence of safety or efficacy, and nothing here is medical advice or a claim about any use in humans or animals.
European journal of medicinal chemistry
Design, synthesis, and structure-activity relationship study of novel GLP-1/GIP/GCG triple receptor agonists